|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0023981,
umls-concept:C0024623,
umls-concept:C0030705,
umls-concept:C0034897,
umls-concept:C0036525,
umls-concept:C0069717,
umls-concept:C0205179,
umls-concept:C0205195,
umls-concept:C0282460,
umls-concept:C0671970,
umls-concept:C0995188,
umls-concept:C1522484,
umls-concept:C1956962
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-2-11
|
|
pubmed:abstractText |
We evaluated the efficacy and safety of cetuximab in combination with XELOX [XELoda® (capecitabine) and OXaliplatin] in advanced gastric cancer (AGC) patients. The objectives were to evaluate overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety of cetuximab plus XELOX.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1573-0646
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
366-73
|
|
pubmed:meshHeading |
pubmed-meshheading:19997960-Adult,
pubmed-meshheading:19997960-Aged,
pubmed-meshheading:19997960-Antibodies, Monoclonal,
pubmed-meshheading:19997960-Antineoplastic Agents,
pubmed-meshheading:19997960-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19997960-Deoxycytidine,
pubmed-meshheading:19997960-Disease-Free Survival,
pubmed-meshheading:19997960-Female,
pubmed-meshheading:19997960-Fluorouracil,
pubmed-meshheading:19997960-Humans,
pubmed-meshheading:19997960-Male,
pubmed-meshheading:19997960-Middle Aged,
pubmed-meshheading:19997960-Neoplasm Metastasis,
pubmed-meshheading:19997960-Neoplasm Staging,
pubmed-meshheading:19997960-Prospective Studies,
pubmed-meshheading:19997960-Receptor, Epidermal Growth Factor,
pubmed-meshheading:19997960-Recurrence,
pubmed-meshheading:19997960-Stomach Neoplasms,
pubmed-meshheading:19997960-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.
|
|
pubmed:affiliation |
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
